Immunic

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immunic and other ETFs, options, and stocks.

About IMUX

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. 

CEO
Daniel Vitt
CEODaniel Vitt
Employees
92
Employees92
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2003
Founded2003
Employees
92
Employees92

IMUX Key Statistics

Market cap
157.53M
Market cap157.53M
Price-Earnings ratio
-1.92
Price-Earnings ratio-1.92
Dividend yield
Dividend yield
Average volume
253.54K
Average volume253.54K
High today
$11.83
High today$11.83
Low today
$11.25
Low today$11.25
Open price
$11.77
Open price$11.77
Volume
137.09K
Volume137.09K
52 Week high
$15.10
52 Week high$15.10
52 Week low
$5.06
52 Week low$5.06

Stock Snapshot

The current Immunic(IMUX) stock price is $11.60, with a market capitalization of 157.53M. The stock trades at a price-to-earnings (P/E) ratio of -1.92.

On 2026-05-20, Immunic(IMUX) stock traded between a low of $11.25 and a high of $11.83. Shares are currently priced at $11.60, which is +3.1% above the low and -1.9% below the high.

The Immunic(IMUX)'s current trading volume is 137.09K, compared to an average daily volume of 253.54K.

In the last year, Immunic(IMUX) shares hit a 52-week high of $15.10 and a 52-week low of $5.06.

In the last year, Immunic(IMUX) shares hit a 52-week high of $15.10 and a 52-week low of $5.06.

IMUX News

TipRanks 17h
Immunic Appoints Michael Bonney as Board Chair

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 7d
Immunic reports Q1 EPS ($1.08), consensus (96c)

“We are fast approaching a highly pivotal juncture, with the anticipated top-line data readout of the twin phase 3 ENSURE trials of our lead asset, orally avail...

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own IMUX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.